Growth and rhGH use in children with congenital chronic kidney disease: a multicentric contemporary study
About half of CKD patients received rhGH treatment, resulting in significant height gain. Untreated patients were not adversely affected in terms of height. These data highlight the importance of careful monitoring of growth and rhGH treatment if needed in patients with CKD.
Authors
- Jean‐Claude Carel (ORCID: https://orcid.org/0000-0002-0424-6767)
- Charlotte Duneton (ORCID: https://orcid.org/0000-0002-0603-1970)
- Séverine Dubois (ORCID: https://orcid.org/0000-0002-8167-7915)
- Tim Ulinski
- Priscilla Boizeau (ORCID: https://orcid.org/0000-0003-4573-4617)
- Dominique Simon
- Rudolf Salomon
Institutions
- Hôpital Necker-Enfants Malades (FR)
- Inserm (FR)
- Délégation Paris 7 (FR)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Institut Necker Enfants Malades (FR)
- Hôpital Armand-Trousseau (FR)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Robert-Debré (FR)
- NeuroDiderot (FR)
Publication Details
- Journal
- Hormone Research in Paediatrics
- Published
- 2025-01-16
- DOI
- https://doi.org/10.1159/000543435
- Citations
- 1
- Primary Topic
- Birth, Development, and Health
- Type
- article
- Field-Weighted Citation Impact
- 3.49